Nanomaterials a Regulatory Challenge for FDA, Report Concludes
FDA’s ability to regulate the safety of dietary supplements using nanomaterials is inadequate due to a lack of information, resources and statutory authority in certain areas, according to a new report released by the Project on Emerging Nanotechnologies (PEN; Washington, DC).
FDA’s ability to regulate the safety of dietary supplements using nanomaterials is inadequate due to a lack of information, resources and statutory authority in certain areas, according to a new report released by the Project on Emerging Nanotechnologies (PEN; Washington, DC).
The report, titled “A Hard Pill To Swallow: Barriers to Effective FDA Regulation of Nanotechnology-Based Dietary Supplements,” details the FDA’s chief problems in regulating nano-enabled dietary supplements. The report also offers a host of recommendations for improving oversight of such products.
"Historically, the regulation of dietary supplements has been a significant challenge for FDA, and the fact that some of those products are now being manufactured using nanotechnology creates an additional layer of complexity," said William B. Schultz, report co-author, and a former FDA official.
Supplement manufacturers are required to disclose limited information about their products under current law, and what information is available is a result of nanotechnology marketing by manufacturers, says the report.
"While it is not possible to precisely determine the prevalence of dietary supplements using engineered nanoparticles, it is likely that the public's exposure to these products will grow significantly in the next several years," said Lisa Barclay, also a co-author of the report.
According to an inventory of federal environmental, health and safety research on nanotechnology maintained by PEN, the U.S. government spends less than $1 million annually to study the direct impact of nanoscale materials on the gastrointestinal tract.
"It is not clear that the supplement industry is conducting the rigorous testing needed either to understand the effects of nanoscale ingredients in its products or to back up the product claims. This means that consumers are potentially exposed to unknown risks that should be balanced with the possible benefits of taking these supplements," said David Rejeski, PEN's director.
Steve Mister on CRN's ongoing lawsuit against New York State
October 11th 2024Nutritional Outlook spoke to The Council for Responsible Nutrition's president and CEO, Steve Mister, at its annual meeting, Convergence '24. Mister discussed the latest in its ongoing lawsuit against NY State's law banning the sale of weight management and muscle building products to minors.
The Nutritional Outlook Podcast Episode 34: Demystifying Prebiotics and Postbiotics
September 30th 2024In this episode of the Nutritional Outlook Podcast we are looking back on a webcast Nutritional Outlook hosted in May, called “Demystifying the Prebiotic and Postbiotic Markets.” During that event, Sandra Saville, director of education and communication for the International Probiotics Association and Dr. Jessica A. Younes, scientific director of the International Probiotics Association debunked myths about prebiotic and postbiotics, and defined the respective categories to help manufacturers better understand how to responsibly formulate and market prebiotic and postbiotic products.
Balchem’s Newest Launch Optifolin⁺® Brings Innovation to the Folate Market
September 19th 2024Supplement launches featuring 5-MTHF are on the rise with double digit growth. In this episode of Nutritional Outlook’s podcast, we explore Optifolin⁺, a new ingredient in the market that offers essential nutrition from prenatal through adulthood. Join us as we uncover the potential impact of the next evolution in folate, setting the stage for a healthier future.
